Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: Enhanced expression by macrophages

Blood

Volumn 103, Issue 1, 2004, Pages 317-324

  Brownstein, Carrie ^a   Deora, Arunkumar B ^a   Jacovina, Andrew T ^a   Weintraub, Rebecca ^a   Gertler, Menard ^a   Faisal Khan, K M ^a   Falcone, Domenick J ^a   Hajjar, Katherine A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; LIPOCORTIN 2; MESSENGER RNA; PLASMINOGEN; THIOGLYCOLIC ACID; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CATALYSIS; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HOST RESISTANCE; HUMAN; HUMAN CELL; LEUKOCYTE; MACROPHAGE; MONOCYTE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 0348227660     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1304     Document Type: Article

References (73)

1. Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med. 1999;9:128-138.
2. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994-1004.
3. Falcone DJ, Borth W, Faisal Khan KM, Hajjar KA. Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Blood. 2001;97:777-784.
4. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen and tissue plasminogen activator, I: identity with annexin II. J Biol Chem. 1994;269:21191-21197.
5. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator, II: annexin II-mediated enhancement of t-PA-dependent plasminogen activation, J Biol Chem. 1994;269:21198-21203.
6. Faller DV, Mentzer SJ. Monocyte and macrophage development and function. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1995:751-762.
7. Luscinskas FW, Gimbrone MA. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med. 1996;47:413-421.
8. Etzioni A, Doerschuk CM, Harlan JM. Of mouse and man: leukocyte and endothelial adhesion molecule deficiencies. Blood. 1999;94:3281-3288.
9. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235-1242.
10. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2:289-300.
11. Vu T, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93:411-422.
12. Felez J, Chanquia CJ, Levin EG, Miles LA, Plow EF. Binding of tissue plasminogen activator to human monocytes and monocytoid monoytold cells. Blood. 1991;78:2318-2327.
13. Felez J, Chanquia CJ, Febregas P, Plow EF, Miles LA. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood. 1993;82:2433-2441.
14. Felez J, Miles LA, Plescia J, Plow EF. Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol. 1990;111:1673-1683.
15. Felez J, Miles LA, Febregas P, Jardi M, Plow EF, Lijnen HR. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb Haemost. 1996;76:577-584.
16. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry. 1991;30:1682-1691.
17. Hart PH, Burgess DR, Vitti GF, Hamilton JA. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood. 1989;74:1222-1225.
18. Hart PH, Vitti GF, Burgess DR, Singleton DK, Hamilton JA. Human monocytes can produce tissue-type plasminogen activator. J Exp Med. 1989;169:1509-1514.
19. Steins MB, Padro T, Li CX, et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis. 1999;145:173-180.
20. Schneiderman J, Bordin GM, Engelberg I, et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall: a possible mechanism for aneurysm expansion. J Clin Invest. 1995;96:639-645.
21. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci. 2002;22:3352-3358.
22. Ferrier GM, McEvoy A, Evans CE, Andrew JG. The effect of cyclic pressure on human monocyte-derived macrophages in vitro. J Bone Joint Surg. 2000;82-B:755-759.
23. Devaraj S, Hugou I, Lialal I. α-Tocopherol decreases CD36 expression in human monocyte-derived macrophages in vitro. J Lipid Res. 2001;42:521-527.
24. + cell-derived dendritic cells and monocytes with lymphocytetropic and monocyte-tropic HIV-1 strains. J Immunol. 1997;158:5035-5042.
25. + peripheral blood monocytes. J Immunol. 1996;157:3850-3859.
26. Czerniecki BJ, Carter C, Rivoltini L, et al. Calciur ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol. 1997;159:3823-3837.
27. Reddy VY, Zhang QY, Weiss SJ. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acac Sci U S A. 1995;92:3849-3853.
28. Lopez M, Martinache C, Canepa S, Chokri M, Scotto F, Bartholeyns J. Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, 11-3, and M-CSF, their differentiation into macrophages. J Immunol Methods. 1993;159:29-38.
29. Hajjar KA, Guevara CA, Lev E, Dowling K, Chacko J. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface: essential role of endonexin repeat 2. J Biol Chem. 1996;271:21652-21659.
30. Hajjar KA, Hamel NM. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator an urokinase. J Biol Chem. 1990;265:2908-2916.
31. Wroblewski F, LaDue JS. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med. 1955;90:210-213.
32. Marmorstein AD, Zurzolo C, Le Bivic A, Rodriguez-Boulan E. Cell surface biotinylation techniques and determination of protein polarity. In: Cells, JE, ed. Cell Biology: A Laboratory Handbook. 1998;4:341-350.
33. Hajjar KA. The endothelial cell tissue plasminogen activator receptor: specific interaction with plasminogen. J Biol Chem. 1991;266:21962-21970.
34. Jacevina AT, Zheng F, Khazaneva E, Lev E, Deera AB, Hajjar KA. Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation. J Biol Chem. 2001;276:49350-49358.
35. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem. 1986;261:11656-11662.
36. Falcone DJ, Ferenc MJ. Acetyl-LDL stimulates macrophage-dependent plasminogen activation and degradation of extracellular matrix. J Cell Physiol. 1988;135:387-396.
37. Hajjar KA, Maud L, dacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain: direct modulation by homocysteine. J Biol Chem. 1998;273:9987-9993.
38. Pepper MS, Montesano R, Mandriota S, Orci L, Vassalli JD. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996;49:138-162.
39. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol. 1988;107:1589-1598.
40. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987;214:187-191.
41. Van den Eijnden MM, Steenhauer SI, Reitsma PH, Bertina RM. Tissue factor expression during monocyte-macrophage differentiation. Thromb Haemost. 1997;77:1129-1136.
42. McKnight AJ, Gordon S. Membrane molecules as differentiation antigens of murine macrophages. Adv Immunol. 1998;68:271-314.
43. Carmeliet P, Moons L, Ploplis VA, Plow EF, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200-208.
44. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol. 1998;18:1035-1045.
45. Heymans S, Luttun AND, Theilmeier G, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
46. Moons L, Wi C, Ploplis V, et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest. 1998;102:1788-1797.
47. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood. 1998;91:2005-2009.
48. Carmeliet P, Moons L, Herbert JM, et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 1997;81:829-839.
49. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439-444.
50. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol. 2000;156:1865-1873.
51. Kitching AR, Holdsworth SR, Ploplis VA, et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med. 1997;185:963-968.
52. Gyetko MR, Chen G-H, McDonald RA, et al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J Clin Invest. 1996;97:1818-1826.
53. Beck JM, Preston AM, Gyetko MR. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice. Infect Immun. 1999;67:879-884.
54. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol. 2001;167:1047-1052.
55. Tsirka S, Gualandris A, Amaral D, Strickland S. Excitotoxin induced neuronal degeneration and seizure are mediated by tissue-type plasminogen activator. Nature. 1995;377:340-344.
56. Rogove AD, Siao CJ, Keyt B, Strickland S, Tsirka SE. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci. 1999;112:4007-4016.
57. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci. 2002;22:3352-3358.
58. Akassoglou K, Kombrinck KW, Degen JL, Strickland S. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol. 2000;149:1157-1166.
59. Knecht M. Plasminogen activator is associated with the extracellular matrix of ovarian granulosa cells. Mol Cell Endocrinol. 1988;56:1-9.
60. Salame MY, Samane NJ, Masood I, deBono DP. Expression of the plasminogen activator system in the human vascular wall. Atheroslcerosis. 2000;152:19-28.
61. Xiao Y, Bunn CL, Bartold PM. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts. J Periodontal Res. 1998;33:17-26.
62. Saksela O, Hovi T, Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J Cell Physiol. 1985;122:125.
63. Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med. 1984;159:1653-1668.
64. Chen ZL, Strickland SE. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917-925.
65. Ott U, Odermatt E, Engel J, Furthmayr H, Timpl R. Protease resistance and conformation of laminin. Eur J Biochem. 1982;123:63-72.
66. Haraguchi M, Border WA, Huang Y, Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int. 2001;59:2146-2155.
67. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest. 2000;106:1441-1443.
68. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Vergilio JA, Nicholson AC. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 1993;268:11951-11958.
69. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor beta 1. J Cell Biol. 1989;109:309-315.
70. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol. 1993;157:528-534.
71. Pendurthi UR, Ngyuen M, Andrade-Gordon P, Petersen LC, Rao LVM. Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signalling pathway. Arterioscler Thromb Vasc Biol. 2002;22:1421-1426.
72. Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells. J Biol Chem. 2002;277:33564-33570.
73. Yang J, Shultz RW, Mars WM, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest. 2002;110:1525-1538.